CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. ...

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value. Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana ...

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value. Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana ...

Core Insights - Cosmos Health Inc. participated in the World Health Expo Dubai 2026, one of the largest healthcare exhibitions globally, held from February 9-12, 2026 [1][3] - The event attracted over 235,000 visitors and 4,300 exhibitors from more than 180 countries, facilitating collaboration among healthcare leaders and innovators [3] Company Highlights - Cosmos Health showcased its proprietary nutraceutical and wellness brands, particularly the Sky Premium Life® line, which is gaining traction through expanded distribution and new product introductions [4][6] - The company also highlighted other brands such as C-Scrub®, an antiseptic wash, and Mediterranation®, a luxury nutritional supplement line featuring organic herbs from the Mediterranean [5][6] - The participation at the Expo allowed Cosmos Health to raise awareness of its manufacturing capabilities and engage with potential partners and distributors [6] Strategic Goals - CEO Greg Siok emphasized the company's commitment to expanding its global footprint and strengthening strategic relationships during the Expo [7] - The company is focused on disciplined growth, brand development, and long-term value creation, with ongoing discussions for potential agreements in regions including Japan, China, and Latin America [7] Company Overview - Cosmos Health Inc., incorporated in 2009, is a diversified global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands [8] - The company operates under European Good Manufacturing Practices and is involved in manufacturing pharmaceuticals, food supplements, and medical devices within the EU [8] - Cosmos Health is expanding its distribution across Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [8]

CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company’s disciplined, opportunistic, and flexible approach to capital deployment. The Company’s digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pi ...

Core Viewpoint - Cosmos Health Inc. continues to experience operational growth and infrastructure expansion through its subsidiary Cosmofarm, particularly in the pharmaceutical distribution sector in Greece [1]. Group 1: Customer Growth and Financial Performance - In 2025, Cosmofarm added nearly 100 new pharmacy customers, resulting in a 20% increase in its active customer base [2]. - Annual revenue per customer increased by approximately 12%, while profitability per customer improved by around 14%, attributed to enhanced route density and optimized order execution [2]. - Management anticipates that customer growth will continue at similar or higher rates in 2026 based on current onboarding activity and demand trends [2]. Group 2: Infrastructure and Automation Investments - Cosmofarm introduced three new delivery routes in the Attica region to enhance service quality and last-mile delivery performance [3]. - The company has made multi-million dollar investments in automation and logistics infrastructure, including advanced robotic systems for procurement and order fulfillment [4]. - A capital investment program of approximately $1 million is currently underway to expand robotic capacity and throughput [4]. Group 3: Revenue Potential and Operational Efficiency - The expanded ROWA and A-frame robotic picking line is expected to materially increase processing capacity and support an incremental annual revenue potential of approximately $40 million [7]. - The company is upgrading its 29,000-square-foot property in Athens to modernize office space and enhance distribution capabilities [8]. - CEO Greg Siokas emphasized that ongoing investments in automation will significantly expand capacity and support sustainable growth and long-term value creation for Cosmos Health [10].

Core Viewpoint - Zacks Small-Cap Research has initiated coverage on Cosmos Health Inc. with a valuation of $4.50 per share, highlighting the company's diversified revenue base and improving financial performance as key factors supporting this valuation [1][2][3]. Valuation Methodology - The valuation is based on a five-year discounted cash flow (DCF) analysis using a 20% discount rate, reflecting the company's small-cap profile and execution risk, with assumptions of moderate near-term revenue growth and a 2% terminal growth rate [4]. Revenue Growth Outlook - Cosmos Health's revenues are projected to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, and further to over $130 million by 2027, driven by higher-margin pharmaceutical products and technology-enabled services [5]. Vertically Integrated Healthcare Platform - The company operates a vertically integrated model that includes pharmaceutical distribution, GDP-compliant wholesale operations, GMP-certified manufacturing, proprietary nutraceutical brands, telehealth services, and AI-enabled R&D [6]. U.S. Market Entry - Cosmos Health is expanding into the U.S. market, highlighted by the acquisition of ZipDoctor, a telehealth subscription platform, and the launch of Sky Premium Life in the U.S. nutraceutical market [7]. Advancing R&D Pipeline - The company is advancing its R&D programs, including CCX0722 for obesity and weight management, and other compounds targeting multiple sclerosis and oncology-related indications [8]. AI-Driven Innovation - The acquisition of Cloudscreen, an AI-enabled drug repurposing platform, is identified as a key technology supporting Cosmos Health's R&D activities, aimed at shortening development timelines and reducing costs [9]. Digital Assets and Blockchain Strategy - Cosmos Health has implemented a digital asset allocation program, including the purchase of Ethereum (ETH), supported by a financing facility of up to $300 million, and has partnered with Prime Ledger LLC for managing digital assets [10]. Improving Financial Performance - The company reported a record third quarter in 2025, with double-digit year-over-year revenue growth, significantly higher gross profit, and improved adjusted EBITDA, reflecting operational execution and a shift toward higher-margin activities [11].

Core Insights - Cosmos Health Inc. has announced a long-term strategic partnership with Prime Ledger LLC to enhance its financial operations through digital transformation and treasury management [1][2] - The partnership will focus on the tokenization of high-value intellectual property (IP) assets, allowing Cosmos Health to explore new capitalization channels [3] - The initial phase of the collaboration will begin in Q4 2025, concentrating on strategy, regulatory mapping, and architectural design for treasury and tokenization platforms [5] Financial Operations - The partnership includes the management of Cosmos Health's $300 million treasury facility, with Prime Ledger implementing advanced controls and reporting systems to improve efficiency and security [2] - A secure framework for Digital Asset Treasury (DAT) management will be established to manage risk, yield, and income in corporate treasury operations [2] Tokenization and Data Management - Prime Ledger will design a token issuance platform for Cosmos Health, facilitating the tokenization of various IP assets [3] - The integration of Cosmos Health's data infrastructure with Prime Ledger's existing relationship with Conduit Network will enhance management of on-chain and off-chain data for financial reporting and compliance [4] Company Background - Cosmos Health Inc. is a diversified global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands, and it operates under European Good Manufacturing Practices [7] - The company is expanding its reach in Europe, Asia, and North America, and has established R&D partnerships targeting major health disorders [7]

Core Insights - Cosmos Health Inc. has seen significant share acquisitions by CEO Greg Siokas, who purchased 301,101 shares between November 19 and November 28, 2025, increasing his total ownership to 6,459,985 shares [1][2][3] - The company reported record-breaking Q3 2025 results, with strong growth across all core business segments, yet its valuation remains under pressure despite these achievements [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning a portfolio of proprietary pharmaceutical and nutraceutical brands [4] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [4] - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders enhanced by artificial intelligence technologies [4] Recent Developments - CEO Greg Siokas has expressed strong confidence in the company's future, stating that he has increased his ownership by over 3 million shares since the beginning of 2025, indicating a commitment to support the company's objectives [2][3] - The company is expanding its global distribution platform throughout Europe, Asia, and North America, with offices and distribution centers in Greece and the UK [4]

Core Insights - Cosmos Health Inc. has initiated a new research and development program utilizing nanotechnology to enhance the effectiveness of phytochemical constituents in dietary supplements [1][2] - The new initiative builds on the proprietary technology developed during the creation of CCX Hydrogel, focusing on plant-based extract-loaded phytosomes to improve absorption, stability, and bioactivity of phytochemicals [2][5] - The company emphasizes a sustainable, solvent-free process for creating phytosomes, aligning with its commitment to environmentally responsible practices [3][5] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [6] - The company manufactures a range of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, under European Good Manufacturing Practices (GMP) [6] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [6]